GlassScriptPhysician profile
Zenobio Aguila
NPI 1205882164
$3,209.37
in general payments reported to CMS, 2019-2025
32 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $221 · 2022: $698 · 2023: $314 · 2024: $495 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $332.90 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $281.65 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $256.12 | 2022-2024 | |
| Pfizer INC. | $245.45 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $228.56 | 2019-2025 | Airsupra, Evusheld |
| Glaxosmithkline, LLC. | $219.24 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.32 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $172.72 | 2019-2024 | Mounjaro, Zepbound, Baqsimi |
| Merck Sharp & Dohme LLC | $165.46 | 2019-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Allergan, INC. | $158.31 | 2019 | |
| Leo Pharma INC. | $125.00 | 2023 | Adbry |
| Astellas Pharma US INC | $99.42 | 2020-2025 | Veozah |
| Exact Sciences Corporation | $82.94 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $68.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.46 | 2019-2024 | Xarelto |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $50.58 | 2019-2020 | |
| Abbvie INC. | $50.03 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $46.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.08 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.44 | 2022 | |
| Abbott Laboratories | $40.52 | 2022-2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $38.77 | 2024 | Voquezna |
| Dexcom, INC. | $36.34 | 2022-2024 | Dexcom G6 Transmitter |
| Nevro Corp. | $22.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.85 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.70 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.69 | 2022 | |
| Genentech USA, INC. | $15.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.69 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.32 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $13.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zenobio Aguila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.